Errata (DOI:10.1016/S1473-3099(08)70180-4);Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa

The Lancet Infectious Diseases

Volumn 8, Issue 8, 2008, Pages 477-489

  Sutcliffe, Catherine G ^a   van Dijk, Janneke H ^b   Bolton, Carolyn ^c   Persaud, Deborah ^d   Moss, William J ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Malaria/Medical Institute at Macha   (Zambia)

^c CENTRE FOR INFECTIOUS DISEASE RESEARCH IN ZAMBIA   (Zambia)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

AFRICA; ALLERGIC DISEASE; AMYLASE BLOOD LEVEL; ANEMIA; CHILD; CHILD HEALTH CARE; CONJUNCTIVITIS; DERMATITIS; DIARRHEA; DRUG EFFICACY; EARLY DIAGNOSIS; GASTROINTESTINAL SYMPTOM; HEADACHE; HEALTH SERVICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIVER DISEASE; LIVER TOXICITY; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; NEUTROPENIA; NUTRITIONAL SUPPORT; PANCREATITIS; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RASH; REVIEW; RURAL HEALTH CARE; SIDE EFFECT; SKIN ALLERGY; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; STOMACH PAIN; TASTE DISORDER; TREATMENT OUTCOME; VIRUS DIAGNOSIS; VOMITING;

EID: 47549096477     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(09)70318-4     Document Type: Erratum

References (108)

1. UNAIDS. UNAIDS fact sheet: sub-Saharan Africa (2006), UNAIDS, Geneva
2. Newell M., Coovadia H., Cortina-Borja M., et al. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 364 (2004) 1236-1243
3. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Progress report, April 2007 (2007), World Health Organization, Geneva
4. International Treatment Preparedness Coalition. Missing the target #3: stagnation in AIDS treatment scale up puts millions of lives at risk. International Treatment Preparedness Coalition, 2006.
5. Harries A., Nyangulu D., Hargreaves N., et al. Preventing antiretroviral anarchy in sub-Saharan Africa. Lancet 358 (2001) 410-414
6. Stevens W., Kaye S., and Corrah T. Antiretroviral therapy in Africa. BMJ 328 (2004) 280-282
7. De Baets A., Bulterys M., Abrams E., et al. Care and treatment of HIV-infected children in Africa: issues and challenges at the district hospital level. Pediatr Infect Dis J 26 (2007) 163-173
8. Fransman D., McCulloch M., Lavies D., et al. Doctors' attitudes to the care of children with HIV in South Africa. AIDS Care 12 (2000) 89-96
9. Rouet F., Fassinou P., Inwoley A., et al. Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens. AIDS 20 (2006) 2315-2319
10. Chaix M., Rouet F., Kouakoussui K., et al. Genotypic human immunodeficiency virus type 1 drug resistance in highly active antiretroviral therapy-treated children in Abidjan, Côte d'Ivoire. Pediatr Infect Dis J 24 (2005) 1072-1076
11. Elise A., France A., Louise W., et al. Assessment of adherence to highly active antiretroviral therapy in a cohort of African HIV-infected children in Abidjan, Côte d'Ivoire. J Acquir Immune Defic Syndr 40 (2005) 498-500
12. Kouakoussui A., Fassinou P., Anaky M., et al. Respiratory manifestations in HIV-infected children pre- and post-HAART in Abidjan, the Ivory Coast. Paediatr Respir Rev 5 (2004) 311-315
13. Fassinou P., Elenga N., Rouet F., et al. Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire. AIDS 18 (2004) 1905-1913
14. Timite-Konan A., Fassinou P., Adonis-Koffy L., et al. Use of antiretroviral drugs in HIV infected children in a tropical area: a real benefit. Arch Pediatr 10 (2003) 831-832
15. Nyandiko W., Ayaya S., Nabakwe E., et al. Outcomes of HIV-infected orphaned and non-orphaned children on antiretroviral therapy in western Kenya. J Acquir Immune Defic Syndr 43 (2006) 418-425
16. Ble C., Floridia M., Muhale C., et al. Efficacy of highly active antiretroviral therapy in HIV-infected, institutionalized orphaned children in Tanzania. Acta Paediatr 96 (2007) 1090-1094
17. O'Brien D., Sauvageot D., Zachariah R., et al. In resource-limited settings good early outcomes can be achieved in children using adult fixed-dose combination antiretroviral therapy. AIDS 20 (2006) 1955-1960
18. Marazzi M., Germano P., Liotta G., et al. Pediatric highly active antiretroviral therapy in Mozambique: an integrated model of care. Minerva Pediatr 58 (2006) 483-490
19. Walker A., Mulenga V., Ford D., et al. The impact of daily cotrimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Clin Infect Dis 44 (2007) 1361-1367
20. Eley B., Nuttall J., Davies M., et al. Initial experience of a public sector antiretroviral treatment programme for HIV-infected children and their infected parents. S Afr Med J 94 (2004) 643-646
21. Eley B. Addressing the paediatric HIV epidemic: a perspective from the Western Cape Region of South Africa. Trans R Soc Trop Med Hyg 100 (2006) 19-23
22. Zampoli M., Kilborn T., and Eley B. Tuberculosis during early antiretroviral-induced immune reconstitution in HIV-infected children. Int J Tuberc Lung Dis 11 (2007) 417-423
23. Reddi A., Leeper S., Grobler A., et al. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr 7 (2007) 13
24. Jooste J., Van Zyl A., Baker A., et al. Antiretroviral treatment in the Northern Cape. S Afr Med J 95 (2005) 812
25. Bikaako-Kajura W., Luyirika E., Purcell D., et al. Disclosure of HIV status and adherence to daily drug regimens among HIV-infected children in Uganda. AIDS Behav 10 suppl (2006) S85-S93
26. Diack M., Signate S.H., Diagne G.N., et al. Epidemiological and clinical aspects of paediatric HIV infections in Albert-Royer Paediatric Hospital (Dakar, Senegal). Arch Pediatr 12 (2005) 404-409
27. Nabukeera-Barungi N., Kalyesubula I., Kekitiinwa A., et al. Adherence to antiretroviral therapy in children attending Mulago Hospital, Kampala. Ann Trop Paediatr 27 (2007) 123-131
28. Malawi Paediatric Antiretroviral Treatment Group. Antiretroviral therapy for children in the routine setting in Malawi. Trans R Soc Trop Med Hyg 101 (2007) 511-516
29. Bong C., Yu J., Chiang H., et al. Risk factors for early mortality in children on adult fixed-dose combination antiretroviral treatment in a central hospital in Malawi. AIDS 21 (2007) 1805-1810
30. Eley B., Davies M., Apolles P., et al. Antiretroviral treatment for children. S Afr Med J 96 (2006) 988-993
31. Wamalwa D., Farquhar C., Obimbo E., et al. Early response to highly active antiretroviral therapy in HIV-1-infected Kenyan children. J Acquir Immune Defic Syndr 45 (2007) 311-317
32. Nyandiko-Mokaya W, Ayaya S, Nabakwe E, et al. Outcomes of HIV-infected orphaned and non-orphaned children on antiretroviral therapy in western Kenya. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract WEPE0089.
33. Wiehe SE, Vreeman RC, Musick BS, et al. Orphan status and pediatric anti-retroviral therapy adherence in a resource-poor setting. Proceedings of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WEPEB095.
34. Obimbo E, Wamalwa D, Inwani I, et al. Model of comprehensive care for HIV-infected children in Nairobi, Kenya. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract CDB0572.
35. Wamalwa D, Farquhar C, Obimbo E, et al. Adherence and early response to highly active antiretroviral therapy in Kenyan children. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract TUPE0104.
36. Olson D, Sauvageot D, Ferradini L, et al. Antiretroviral therapy (ART) outcomes in children <13 years of age in resource-poor countries (RPCs): a Medecins Sans Frontieres (MSF) cohort. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract MOAB0204.
37. Humblet P, Calmy A, Pinoges L, et al. Offering HAART to children in resource-poor settings: the experience of Medecins Sans Frontieres. Proceedings of the XV International AIDS Conference 2004; July 11-16, 2004; Bangkok, Thailand. Abstract TuPeB4461.
38. Liotta G, Germano P, Palombi L, et al. Pediatric HAART in resource-limited settings: the DREAM model of care. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract THPE0178.
39. Nuttall J, Eley B, Davies MA, et al. Serious medical events in children during the first six months of HAART. Proceedings of the XV International AIDS Conference 2004; July 11-16, 2004; Bangkok, Thailand. Abstract TuPeB4414.
40. Eley B, Nuttall J, Davies MA, et al. Initial experience of a public sector antiretroviral treatment programme for HIV-infected children in Cape Town, South Africa. Proceedings of the XV International AIDS Conference 2004; July 11-16, 2004; Bangkok, Thailand. Abstract TuPeB4412.
41. Reddi A, Leeper S, Grobler A, et al. Outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract WEPE0117.
42. Nkengasong J, Adje-Toure C, Hanson D, et al. Virologic and immunologic response to ART and predictors of HIV-1 drug resistance in children receiving treatment in Abidjan, Côte d'Ivoire. Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections; Feb 25-28, 2007; Los Angeles, CA, USA. Abstract 729.
43. Mahan L, Kouakoussui A, Toure S. Following-up a children HIV-infected cohort in the context of extending access to care for PLWH in Abidjan, Côte d'Ivoire. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract CDB0538.
44. Kline M, Anabwani G, Kekitiinwa A, et al. Catalyzing the care and treatment of HIV-infected children in sub-Saharan Africa: early outcomes from 5 Baylor College of Medicine Centers. Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections; Feb 25-28, 2007; Los Angeles, CA, USA. Abstract 79.
45. Carter R, Katyal M, Austin J, et al. Age and CD4 percentage at ART initiation: relationship to CD4 response over time among children enrolled in MTCT-plus initiative sites. Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections; Feb 25-28, 2007; Los Angeles, CA, USA. Abstract 730.
46. Warren H, Bruce D, Armstrong D, et al. The effect of ARV treatment, counseling and adherence support on CD4 counts in an HIV(+) pediatric population. Proceedings of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract CDB343.
47. Kamya MR, Mayanja-Kizza H, Kambugu A, et al. Predictors of long-term viral failure among Ugandan children and adults treated with ART and monitored using clinical and immunologic criteria. Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections; Feb 25-28, 2007; Los Angeles, CA, USA. Abstract 732.
48. Nannyonga Musoke M, Morelli E, Atai B, et al. Efficacy of HAART in Ugandan HIV-infected children. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract MOPE0246.
49. Ajuna P, Mubiru M, Barlow-Mosha L, et al. Comparing clinical versus immunological and virological responses to HAART in HIV-infected Ugandan children on Triomune. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract WEPE0100.
50. Luyirika E, Finkbeiner T, Nabiddo L, et al. Antiretroviral therapy for HIV-infected children in Uganda, 2004-05. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract WEPE0111.
51. Alexander L, Mubiru M, Were W, et al. Virologic, immunologic and clinical outcomes in Ugandan children initiating antiretroviral treatment. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract CDB0555.
52. Ahoua L, Guenther G, Pinoges L, et al. Children antiretroviral treatment outcomes after 12 or 24 months of HAART in the HIV care program of North-Western Uganda. Proceedings of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract TUPEB132.
53. Kariyo P, Ntwari R, Baramperanye E, et al. Clinical and immunological responses to triple combination antiretroviral therapy in burundian children. Proceedings of the XV International AIDS Conference 2004; July 11-16, 2004; Bangkok, Thailand. Abstract B10538.
54. Kariyo P, Mbuzenakamwe M, Baramperanye E, et al. Antiretroviral therapy in a hundred Burundian children with AIDS. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract MOPE0208.
55. Weigel R, Tauzi J, Thambo L, et al. Characteristics of HIV-infected children <13 years receiving highly active antiretroviral therapy (HAART) at Lighthouse clinic at Lilongwe Central Hospital (LCH), Lilongwe, Malawi. Proceedings of the XV International AIDS Conference 2004; July 11-16, 2004; Bangkok, Thailand. Abstract B10559.
56. Anabwani G, Lowenthal E, Marape M, et al. Long term response to highly active antiretroviral therapy among treatment naive children in Botswana. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract MOPE0261.
57. Jibril H, Bowman D, Kurup S, et al. Response to antiretroviral therapy among treatment naive children in Botswana. Proceedings of the XV International AIDS Conference 2004; July 11-16, 2004; Bangkok, Thailand. Abstract TuOrB1191.
58. Woldetsadik E, Anabwani G, Bowman D, et al. Adverse drug reactions (ADR) among antiretroviral naive HIV infected children in Botswana. Proceedings of the XV International AIDS Conference 2004; July 11-16, 2004; Bangkok, Thailand. Abstract TuPeB4421.
59. Mbewe M, Bolton C, Levy J, et al. Children enrolled in a public HIV care and treatment program in Lusaka, Zambia: rapid scale-up and first-year clinical outcomes. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract MOA0201.
60. Naidoo K, Krishna M, Suleman M, et al. Evaluation of the changes in haematological parameters of 500 children on antiretroviral medication. Experience from Pietermaritzburg, Kwa-ZuluNatal, South Africa. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract WEPE0102.
61. Vilakazi P, Naidoo K, Krishna M, et al. Using attendance records as surrogate markers of adherence in resource poor settings. An assessment of attendance and outcomes amongst the first 800 paediatric patients attending antiretroviral clinics in Pietermaritzburg, Kwa-Zulu Natal, South Africa. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract CDB0783.
62. Archary M, Bobat R. The outcomes of the first 100 ART naive paediatric patients initiated on highly active antiretroviral treatment (HAART) in a resource-limited setting in Durban, South Africa. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract CDB0559.
63. Archary M, Bobat R. The effect of highly active antiretroviral treatment (HAART) on serum albumin and serum globulin: a 12 month review of paediatric patients at King Edward VIII Hospital. Proceedings of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract CDB064.
64. Moultrie H, Meyers T. Audit of children on antiretroviral therapy in a government sector clinic in Soweto, South Africa. Proceedings of the XV International AIDS Conference 2004; July 11-16, 2004; Bangkok, Thailand. Abstract TuPeB4423.
65. Coetzee D, Hilderbrand K, Boulle A, et al. Paediatric outcomes after 3 years in a primary care setting in South Africa. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract MOPE0223.
66. White J, Armstrong R, Lekena L, et al. Preliminary outcomes of providing antiretroviral therapy to children at a public sector HIV clinic in Lesotho, southern Africa. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract THPE0213.
67. Nalubega M, Mubiru M, Musoke B, et al. Adherence to HAART in HIV-infected Ugandan children on Triomune. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract MOPE0232.
68. Nabacwa S. HAART treatment outcomes in children: the case of Nsambya home care ART project in Uganda. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract CDB0998.
69. Mukhtar-Yola M, Adeleke S, Gwarzo D, et al. Preliminary investigation into adherence in children receiving antiretroviral therapy in Aminu Kano teaching hospital Kano, Nigeria. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract CDB1018.
70. De Naeyer L, van Griensven J, Ubarijoro S, et al. HAART can be provided safely in African HIV positive children: analysis of patients in 2 urban health centres in Kigali. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract MOPE0242.
71. Tene G, Kissougle F, Tietche F, et al. Treatment compliance among HIV-infected children treated with HAART at the mother and child centre of the Chantal Biya foundation in Yaounde, Cameroon. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract CDB0823.
72. Nabukeera N, Kekitinwa A, Kalyesubula I, et al. Adherence to antiretroviral therapy among children in Mulago hospital in Uganda. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract TUPE0136.
73. Makwiza I, Weigel R, Chiunguzeni D, et al. Children and adherence to ART: what are the social and system-related challenges? Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract CDB0767.
74. Vaz P, Thome B, Macassa E, et al. Large paediatric experience of antiretroviral treatment in Maputo Public Hospital, Mozambique. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract MOPE0259.
75. Arrive E, Marquis B, Tumwesiye N, et al. Response to ART in children in sub-Saharan Africa: a pooled analysis of clinical databases, the KIDS-ART-LINC Collaboration. Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections; Feb 25-28, 2007; Los Angeles, CA, USA. Abstract 727.
76. Semeere Semwendero A, Kiyingi Samuel H, Okech B, et al. Adherence to antiretroviral therapy in HIV positive children at Nsambya Home Care. Proceedings of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WEPEB092.
77. Amali-Adekwu O, Onotu D, Ochoga M, et al. Outcome of antiretroviral therapy in children in Jos, Nigeria. A preliminary report. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract CDB0493.
78. Feucht U, Gallup C, Wolfman V, et al. Adverse events in therapy-naive HIV-infected children receiving HAART in a single institution in South Africa. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract CDB0714.
79. Songok E, Lwembe R, Ochieng W, et al. Drug resistant mutations in children failing antiretroviral therapy in Kenya. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract THPE0094.
80. WHO. Scaling up antiretroviral therapy in resource-limited settings: treatment guidelines for a public health approach (2004), WHO, Geneva
81. US National Institutes of Health. Guidelines for the use of antiretroviral agents in pediatric HIV infection. http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf (as of June 11, 2008).
82. Barry G, Coovadia A, Marais G, et al. Analysis of HIV-infected infants under 1 year starting antiretroviral treatment at the coronation paediatric HIV clinic in Coronationville, Johannesburg. Proceedings of the XVI International AIDS Conference; Aug 13-18, 2006; Toronto, Canada. Abstract MOPE0233.
83. Gibb D., Newberry A., Klein N., et al. Immune repopulation after HAART in previously untreated HIV-1-infected children. Lancet 355 (2000) 1331-1332
84. Walker A., Doerholt K., Sharland M., et al. Response to highly active antiretroviral therapy varies with age: the UK and Ireland Collaborative HIV Paediatric Study. AIDS 18 (2004) 1915-1924
85. Resino S., Bellón J., Gurbindo D., et al. Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study. Clin Infect Dis 37 (2003) 1216-1225
86. Bracher L., Valerius N., Rosenfeldt V., et al. Long-term effectiveness of highly active antiretroviral therapy (HAART) in perinatally HIV-infected children in Denmark. Scand J Infect Dis 39 (2007) 799-804
87. van Rossum A., Geelen S., Hartwig N., et al. Results of 2 years of treatment with protease-inhibitor-containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1. Clin Infect Dis 34 (2002) 1008-1016
88. Doerholt K., Duong T., Tookey P., et al. Outcomes for human immunodeficiency virus-1-infected infants in the United Kingdom and Republic of Ireland in the era of effective antiretroviral therapy. Pediatr Infect Dis J 25 (2006) 420-426
89. Resino S., Resino R., Micheloud D., et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis 42 (2006) 862-869
90. Simoni J., Montgomery A., Martin E., et al. Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics 119 (2007) e1371-e1383
91. Spira R., Lepage P., Msellati P., et al. Natural history of human immunodeficiency virus type 1 infection in children: a five-year prospective study in Rwanda. Pediatrics 104 (1999) e56
92. van der Loeff M.S., Hansmann A., Awasana A., et al. Survival of HIV-1 and HIV-2 perinatally infected children in The Gambia. AIDS 17 (2003) 2389-2394
93. Taha T., Graham S., Kumwenda N., et al. Morbidity among human immunodeficiency virus-1-infected and uninfected African children. Pediatrics 106 (2000) E77
94. Resino S., Alvaro-Meca A., de Jose M., et al. Low immunologic response to highly active antiretroviral therapy in naive vertically human immunodeficiency virus type 1-infected children with severe immunodeficiency. Pediatr Infect Dis J 25 (2006) 365-368
95. O'Brien D., Sauvageot D., Olson D., et al. Treatment outcomes stratified by baseline immunological status among young children receiving nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in resource-limited settings. Clin Infect Dis 44 (2007) 1245-1248
96. Newell M., Patel D., Goetghebuer T., et al. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation?. J Infect Dis 193 (2006) 954-962
97. Eley B., and Nuttall J. Antiretroviral therapy for children: challenges and opportunities. Ann Trop Paediatr 27 (2007) 1-10
98. Creek T., Tanuri A., Smith M., et al. Early diagnosis of human immunodeficiency virus in infants using polymerase chain reaction on dried blood spots in Botswana's national program for prevention of mother-to-child transmission. Pediatr Infect Dis J 27 (2008) 22-26
99. Knuchel M., Tomasik Z., Speck R., et al. Ultrasensitive quantitative HIV-1 p24 antigen assay adapted to dried plasma spots to improve treatment monitoring in low-resource settings. J Clin Virol 36 (2006) 64-67
100. Violari A, Cotton M, Gibb D, et al. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. Proceedings of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 22-25, 2007; Sydney, Australia. Abstract WESS103.
101. Heikens G., Bunn J., Amadi B., et al. Case management of HIV-infected severely malnourished children: challenges in the area of highest prevalence. Lancet 371 (2008) 1305-1307
102. Obimbo E., Mbori-Ngacha D., Ochieng J., et al. Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected African children. Pediatr Infect Dis J 23 (2004) 536-543
103. Walker A., Mulenga V., Sinyinza F., et al. Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP trial. J Acquir Immune Defic Syndr 42 (2006) 637-645
104. Agnarson A., Ericson J., Ekstrom A., et al. Antiretroviral therapy: what about food?. AIDS 21 (2007) 1225-1226
105. Bobat R., Coovadia H., Stephen C., et al. Safety and efficacy of zinc supplementation for children with HIV-1 infection in South Africa: a randomised double-blind placebo-controlled trial. Lancet 366 (2005) 1862-1867
106. Ellis J., L'Homme R., Ewings F., et al. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther 12 (2007) 253-260
107. Fredlund V., and Nash J. How far should they walk? Increasing antiretroviral therapy access in a rural community in northern KwaZulu-Natal, South Africa. J Infect Dis 196 suppl 3 (2007) S469-S473
108. Bedelu M., Ford N., Hilderbrand K., et al. Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. J Infect Dis 196 suppl 3 (2007) S464-S468